WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Narmin Hajo, Ghazal Dib and Amal Al-Hakim

ABSTRACT

Background: While Guideline recommends daily treatment of corticosteroids to control asthma symptoms, Montelukast, a leukotriene receptor antagonist, is effective in treating asthma symptoms. Objective: To test the hypothesis that combined administration of multiple doses of inhaled Budesonide and oral montelukast provides additional benefit compared with Budesonide alone in children patients with mild and moderate severity of persistent asthma. Methods: An open Randomized trails study included 120 patients presenting to the clinic at Tishreen University Hospital over one year from March 2020 to March 2021. The patients were randomized to two equal groups: inhaled Budesonide only (group A) and inhaled Budesonide with oral montelukast (group B) by inhalation chamber over 12 weeks. All clinical variables by fill out a questionnaire, pulmonary functions (PEF, FEV1) were recorded at the baseline, 6, and 12 weeks. Results: The results showed that adding Montelukast to inhaled Budesonide improves the FEV1, PEF values, and quality of life (decrease the use of beta 2 agonists, the frequency of asthma symptoms, the night symptoms, and the defines activate with a significant difference. Conclusion: This study suggests that there is a therapeutic benefit of adding Montelukast to inhaled Budesonide in the treatment of patients with mild and moderate severity of persistent asthma

[Full Text Article] [Download Certificate]